Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The most novel of the novel agents for acute myeloid leukemia.

Current opinion in hematology - 1 Mar 2018

Perl Alexander E

Abstract excerpt

PURPOSE OF REVIEW: Precious few drugs were successfully developed for acute myeloid leukemia (AML) over the past decades, despite a dramatic expansion of our understanding of its molecular underpinnings during this time. Then in 2017, a wave of new drugs suddenly became approved. This review serves to introduce the newly available drugs, discuss their impact upon therapy, and highlight additional novel agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytotoxins
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCL2 gene

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29278535
DOI: 10.1097/MOH.0000000000000411

Genes

FLT3
BCL2
IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The most novel of the novel agents for acute myeloid leukemia.PMID 29278535Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

Molecularly targeted therapies for acute myeloid leukemia.Semantic proximity Read ↗

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?Semantic proximity Read ↗

Novel Therapeutics in Acute Myeloid Leukemia.Semantic proximity Read ↗

Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting ChallengesSemantic proximity Read ↗

Recent advances in the understanding and treatment of acute myeloid leukemiaSemantic proximity Read ↗

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read ↗

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

‘Acute myeloid leukemia: a comprehensive review and 2016 update’Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.